This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Menu

Close

AboutAboutBroad CoverageIndicationsEfficacyEfficacyEfficacyLimited Treatment OptionsSafetySafetySafetyDosingDosingAdult DosingPaediatric Dosing
Adult Dosing

Consistent dosing across indications1

Recommended dose for adult patients with estimated CrCl ≥51 mL/min (refer to SmPC for full dosing information)*
Scroll left to view table
Type of
Infection		 Dose of ZAVICEFTA (ceftazidime-avibactam)
Frequency
Infusion time		 Duration of treatment
cIAI†‡ 2 g/0.5 g Every 8 hours 2 hours 5–14 days
cUTI, including pyelonephritis‡ 2 g/0.5 g Every 8 hours 2 hours 5–10 days§
HAP, including VAP‡ 2 g/0.5 g Every 8 hours 2 hours 7–14 days
Bacteraemia associated with, or suspected to be associated with, cIAI, cUTI or HAP/VAP 2 g/0.5 g Every 8 hours 2 hours In accordance with the site of infection
Infections due to aerobic Gram-negative organisms in patients with limited treatment options†‡ 2 g/0.5 g Every 8 hours 2 hours Guided by severity of infection, the pathogen(s) and patient’s clinical and bacteriological progress||
  • No dose adjustment required in the elderly, patients with mild renal impairment (estimated CrCl ≥51 to ≤80 mL/min) and those with hepatic impairment.1
The dose of ZAVICEFTA in adult patients with estimated CrCl ≤50 mL/min should be adjusted according to recommended doses. CrCl estimated in adults using the Cockcroft–Gault formula.To be used in combination with metronidazole when anaerobic pathogens are known or suspected to be contributing to the infectious process.To be used in combination with an antibacterial agent active against Gram-positive pathogens when these are known or suspected to be contributing to the infectious process.The total duration shown may include intravenous ZAVICEFTA followed by appropriate oral therapy.There is very limited experience with the use of ZAVICEFTA for more than 14 days.Prescribing information

Zavicefta® (avibactam sodium, ceftazidime pentahydrate)

Zavicefta® (avibactam sodium, ceftazidime pentahydrate) 2g/0.5g powder for concentrate for
solution for infusion)

Abbreviations:cIAI, complicated intra-abdominal infection; CrCl, creatinine clearance; cUTI, complicated urinary tract infection; HAP, hospital-acquired pneumonia; SmPC, Summary of Product Characteristics; VAP, ventilator-associated pneumonia.References:ZAVICEFTA. Summary of Product Characteristics, 2022. Dosing

Legal Category: S1A

Further information available upon request
PP-ZVA-IRL-0241. December 2022

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.

 

Copyright © 2023 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0176. January 2023
For Healthcare Professionals in the Republic of Ireland *

The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.

I confirm that I am a healthcare professional resident in the Republic of Ireland.*

I accept and agree to the terms of use.*

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

PP-UNP-IRL-0176. January 2023

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.